Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
Lead Sponsor:
Imbria Pharmaceuticals, Inc.
Conditions:
Non-obstructive Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
Eligibility Criteria
Inclusion
- Diagnosis of Hypertrophic Cardiomyopathy consistent with current US and European guidelines
- Ability to perform an upright treadmill cardiopulmonary exercise test
- Agreement to abide by contraceptive requirements
Exclusion
- Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
- Women who are pregnant, planning to become pregnant or lactating
- Participation in another clinical study involving a test product or invasive medical device within 28 days (or within 5 elimination half-lives of the respective test product, whichever is longer), prior to first dosing
Key Trial Info
Start Date :
June 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 18 2023
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04826185
Start Date
June 14 2021
End Date
September 18 2023
Last Update
April 23 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Imbria Investigational Site
La Jolla, California, United States, 92093
2
Imbria Investigational Site
Los Angeles, California, United States, 90048
3
Imbria Investigational Site
San Francisco, California, United States, 94143
4
Imbria Investigational Site
Chicago, Illinois, United States, 60611